|Manufacturer:||Bausch & Lomb Incorporated|
Bausch & Lomb Incorporated, Tampa, Florida 33637U.S.
Patent No.5,747,061 ©Bausch & Lomb IncorporatedAlrex® is a registered trademark of Bausch & Lomb Incorporated9007901 (Folded)9005501 (Flat)
ALREX, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.ALREX is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of this preparation and to other corticosteroids.
Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation.
Steroids should be used with caution in the presence of glaucoma.Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections.In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids.In acute purulent conditions of the eye, steroids may mask infection or enhance existing infection.Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution.